BIIB
Price
$136.41
Change
+$0.05 (+0.04%)
Updated
Aug 26, 01:40 PM (EDT)
Capitalization
19.99B
57 days until earnings call
MRK
Price
$85.28
Change
-$0.02 (-0.02%)
Updated
Aug 26, 11:46 AM (EDT)
Capitalization
213.09B
65 days until earnings call
Interact to see
Advertisement

BIIB vs MRK

Header iconBIIB vs MRK Comparison
Open Charts BIIB vs MRKBanner chart's image
Biogen
Price$136.41
Change+$0.05 (+0.04%)
Volume$1.03K
Capitalization19.99B
Merck & Co
Price$85.28
Change-$0.02 (-0.02%)
Volume$5.34K
Capitalization213.09B
BIIB vs MRK Comparison Chart in %
Loading...
BIIB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MRK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BIIB vs. MRK commentary
Aug 26, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BIIB is a Buy and MRK is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 26, 2025
Stock price -- (BIIB: $136.36 vs. MRK: $85.31)
Brand notoriety: BIIB and MRK are both notable
Both companies represent the Pharmaceuticals: Major industry
Current volume relative to the 65-day Moving Average: BIIB: 62% vs. MRK: 73%
Market capitalization -- BIIB: $19.99B vs. MRK: $213.09B
BIIB [@Pharmaceuticals: Major] is valued at $19.99B. MRK’s [@Pharmaceuticals: Major] market capitalization is $213.09B. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $623.33B to $0. The average market capitalization across the [@Pharmaceuticals: Major] industry is $89.13B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BIIB’s FA Score shows that 0 FA rating(s) are green whileMRK’s FA Score has 2 green FA rating(s).

  • BIIB’s FA Score: 0 green, 5 red.
  • MRK’s FA Score: 2 green, 3 red.
According to our system of comparison, MRK is a better buy in the long-term than BIIB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BIIB’s TA Score shows that 6 TA indicator(s) are bullish while MRK’s TA Score has 6 bullish TA indicator(s).

  • BIIB’s TA Score: 6 bullish, 3 bearish.
  • MRK’s TA Score: 6 bullish, 3 bearish.
According to our system of comparison, BIIB is a better buy in the short-term than MRK.

Price Growth

BIIB (@Pharmaceuticals: Major) experienced а +0.33% price change this week, while MRK (@Pharmaceuticals: Major) price change was +1.29% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -0.51%. For the same industry, the average monthly price growth was +2.28%, and the average quarterly price growth was +12.51%.

Reported Earning Dates

BIIB is expected to report earnings on Oct 22, 2025.

MRK is expected to report earnings on Oct 30, 2025.

Industries' Descriptions

@Pharmaceuticals: Major (-0.51% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MRK($213B) has a higher market cap than BIIB($20B). MRK (13.14) and BIIB (13.05) have similar P/E ratio . BIIB YTD gains are higher at: -10.829 vs. MRK (-12.637). MRK has higher annual earnings (EBITDA): 25B vs. BIIB (2.79B). MRK has more cash in the bank: 8.62B vs. BIIB (2.76B). BIIB has less debt than MRK: BIIB (6.6B) vs MRK (35.4B). MRK has higher revenues than BIIB: MRK (63.6B) vs BIIB (10B).
BIIBMRKBIIB / MRK
Capitalization20B213B9%
EBITDA2.79B25B11%
Gain YTD-10.829-12.63786%
P/E Ratio13.0513.1499%
Revenue10B63.6B16%
Total Cash2.76B8.62B32%
Total Debt6.6B35.4B19%
FUNDAMENTALS RATINGS
BIIB vs MRK: Fundamental Ratings
BIIB
MRK
OUTLOOK RATING
1..100
1520
VALUATION
overvalued / fair valued / undervalued
1..100
89
Overvalued
9
Undervalued
PROFIT vs RISK RATING
1..100
10071
SMR RATING
1..100
7326
PRICE GROWTH RATING
1..100
5655
P/E GROWTH RATING
1..100
9491
SEASONALITY SCORE
1..100
150

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MRK's Valuation (9) in the Pharmaceuticals Major industry is significantly better than the same rating for BIIB (89) in the Biotechnology industry. This means that MRK’s stock grew significantly faster than BIIB’s over the last 12 months.

MRK's Profit vs Risk Rating (71) in the Pharmaceuticals Major industry is in the same range as BIIB (100) in the Biotechnology industry. This means that MRK’s stock grew similarly to BIIB’s over the last 12 months.

MRK's SMR Rating (26) in the Pharmaceuticals Major industry is somewhat better than the same rating for BIIB (73) in the Biotechnology industry. This means that MRK’s stock grew somewhat faster than BIIB’s over the last 12 months.

MRK's Price Growth Rating (55) in the Pharmaceuticals Major industry is in the same range as BIIB (56) in the Biotechnology industry. This means that MRK’s stock grew similarly to BIIB’s over the last 12 months.

MRK's P/E Growth Rating (91) in the Pharmaceuticals Major industry is in the same range as BIIB (94) in the Biotechnology industry. This means that MRK’s stock grew similarly to BIIB’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BIIBMRK
RSI
ODDS (%)
N/A
Bearish Trend 1 day ago
57%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
69%
Bearish Trend 1 day ago
67%
Momentum
ODDS (%)
Bullish Trend 1 day ago
58%
Bullish Trend 1 day ago
46%
MACD
ODDS (%)
Bullish Trend 1 day ago
51%
Bullish Trend 1 day ago
45%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
55%
Bullish Trend 1 day ago
50%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
56%
Bullish Trend 1 day ago
46%
Advances
ODDS (%)
Bullish Trend 5 days ago
53%
Bullish Trend 5 days ago
47%
Declines
ODDS (%)
Bearish Trend 28 days ago
70%
Bearish Trend 27 days ago
51%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
75%
N/A
Aroon
ODDS (%)
Bullish Trend 1 day ago
57%
Bullish Trend 1 day ago
60%
View a ticker or compare two or three
Interact to see
Advertisement
BIIB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MRK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
GOOP30.180.28
+0.95%
Kurv Yield Premium Str Google ETF
TPLS25.38-0.01
-0.04%
Thornburg Core Plus Bond ETF
VIXY35.13-0.06
-0.17%
ProShares VIX Short-Term Futures
PHDG36.29-0.12
-0.33%
Invesco S&P 500® Downside Hedged ETF
BSVO22.55-0.17
-0.75%
EA Bridgeway Omni Small-Cap Value ETF